Compare NBP & NGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NBP | NGEN |
|---|---|---|
| Founded | 2014 | 2017 |
| Country | United States | Canada |
| Employees | 30 | 9 |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 225.5M | 197.5M |
| IPO Year | N/A | N/A |
| Metric | NBP | NGEN |
|---|---|---|
| Price | $2.12 | $2.15 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | $9.00 | ★ $18.00 |
| AVG Volume (30 Days) | 698.9K | ★ 844.8K |
| Earning Date | 04-07-2026 | 04-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $1.46 | $1.70 |
| 52 Week High | $5.19 | $5.93 |
| Indicator | NBP | NGEN |
|---|---|---|
| Relative Strength Index (RSI) | 69.52 | 45.40 |
| Support Level | $2.10 | $1.70 |
| Resistance Level | $2.73 | $2.35 |
| Average True Range (ATR) | 0.15 | 0.17 |
| MACD | 0.09 | 0.08 |
| Stochastic Oscillator | 83.98 | 60.87 |
NovaBridge Biosciences operates as a biotechnology platform, combining business development and clinical research to identify and advance pharmaceutical assets. Its inventive immuno-oncology pipeline consists of three clinical stage programs, givastomig; uliledlimab; and ragistomig. Its core product, givastomig, is a potential in-class CLDN18.2 bispecific antibody for the treatment of gastric cancer and other CLDN18.2-positive gastrointestinal malignancies.
NervGen Pharma Corp is a clinical-stage biopharmaceutical company developing first-in-class neuroreparative therapeutics for spinal cord injury and other traumatic and neurologic conditions. The Company's principal business activity is the discovery, development and commercialization of neuroreparative therapeutics for spinal cord injury (SCI) and other neurotraumatic and neurologic conditions. NervGen's initial target indication is SCI. The company's pipeline products include NVG-291 and NVG-300.